TY - JOUR
T1 - Histone deacetylase inhibitors and cell death
AU - Zhang, Jing
AU - Zhong, Qing
N1 - Funding Information:
We thank all Zhong laboratory members for suggestions. The author apologizes to all colleagues whose work may not have been cited for space reasons. Thanks Rhea Sumpter, Mary Grace Lin and Tabitha Ting for critical reading of the manuscript. The work in our lab is supported by grants to Q. Z. from the Welch Foundation, the new investigator award from the Ellison Medical foundation, American Cancer Society Research Scholar Grant (RSG-11-274-01-CCG) and NIH R01 (CA133228).
Publisher Copyright:
© 2014 Springer Basel.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Histone deacetylases (HDACs) are a vast family of enzymes involved in chromatin remodeling and have crucial roles in numerous biological processes, largely through their repressive influence on transcription. In addition to modifying histones, HDACs also target many other non-histone protein substrates to regulate gene expression. Recently, HDACs have gained growing attention as HDAC-inhibiting compounds are being developed as promising cancer therapeutics. Histone deacetylase inhibitors (HDACi) have been shown to induce differentiation, cell cycle arrest, apoptosis, autophagy and necrosis in a variety of transformed cell lines. In this review, we mainly discuss how HDACi may elicit a therapeutic response to human cancers through different cell death pathways, in particular, apoptosis and autophagy.
AB - Histone deacetylases (HDACs) are a vast family of enzymes involved in chromatin remodeling and have crucial roles in numerous biological processes, largely through their repressive influence on transcription. In addition to modifying histones, HDACs also target many other non-histone protein substrates to regulate gene expression. Recently, HDACs have gained growing attention as HDAC-inhibiting compounds are being developed as promising cancer therapeutics. Histone deacetylase inhibitors (HDACi) have been shown to induce differentiation, cell cycle arrest, apoptosis, autophagy and necrosis in a variety of transformed cell lines. In this review, we mainly discuss how HDACi may elicit a therapeutic response to human cancers through different cell death pathways, in particular, apoptosis and autophagy.
KW - Apoptosis
KW - Autophagy
KW - Cell death
KW - Histone deacetylase inhibitor (HDACi)
KW - Histone deacetylases (HDACs)
UR - http://www.scopus.com/inward/record.url?scp=84910019636&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84910019636&partnerID=8YFLogxK
U2 - 10.1007/s00018-014-1656-6
DO - 10.1007/s00018-014-1656-6
M3 - Review article
C2 - 24898083
AN - SCOPUS:84910019636
SN - 1420-682X
VL - 71
SP - 3885
EP - 3901
JO - Cellular and Molecular Life Sciences
JF - Cellular and Molecular Life Sciences
IS - 20
ER -